EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

Last updated: December 19, 2024
Sponsor: Sarah Cockayne
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

Antibiotic - fixed-extended-duration

Antibiotic - standard duration

Clinical Study ID

NCT05148702
NIHR131784
ISRCTN 72819021
  • Ages > 16
  • All Genders

Study Summary

A multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot. A total of 1166 consenting adult patients with cIAI will be recruited and randomised on a 1:1 basis between 28-days antibiotics and standard care antibiotics. Patients will be followed up for 180 days to determine cost effectiveness and the rate of treatment failure in each group.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults (≥ 16 years) with cIAI* (see cIAI definition)

  • Being treated with antibiotics until the point of randomisation, but within 10 daysof initiation of effective antibiotic treatment** for cIAI

  • Ability to provide informed consent by the patient or their consultee.

  • More than 72 hours*** of active in-patient management for the patients cIAI isrequired

  • In the event that the patient is re-admitted to hospital during the trial period,they are likely to be admitted to a hospital participating in the EXTEND trial.

Patients will be included in the trial whether or not they undergo surgical or radiological source control procedures.

  • cIAI is defined by the following case definition:
  • A clinical presentation consistent with cIAI, plus

  • Fever (temperature of ≥ 37.8°C) and/or a neutrophilia (> 7.5×109/L) and/orneutropaenia (<1.8 x 109 /L) and/or intestinal pathogens cultured from sterile sites (closed peritoneum or blood) around the time of cIAI diagnosis, plus

  • Evidence of pathologic findings on radiologic examination, or

  • Evidence of pathologic findings at operation

** The first day of effective antibiotic treatment will be determined by thepatient's clinical team or clinical research team. Antibiotics that do not counttowards these 10 days of effective treatment are:

  • Antibiotic prophylaxis e.g., penicillin for splenectomy, elective surgery antibioticprophylaxis, UTI prophylaxis

  • Treatment for other infections that is not effective for cIAI e.g., cystitis.Antibiotics that re often used for cystitis and aren't effective for cIAI includeCephalexin, Fosfomycin Trimethoprim, Nitrofurantoin, and Pivmecillinam.

  • Oral antibiotics prescribed to treat infection prior to hospitalisation

  • Previous courses of treatment antibiotics: A previous course is one stopped for 48hours or more

  • The further 72 hours starts from the first day of effective antibiotictreatment i.e., for a patient admitted to hospital with a cIAI, 3 days ofadmission are needed. Where a patient is already in hospital e.g., a postoperative patient, a further 3 days of admission are required starting from thepoint of the first day of effective antibiotic treatment.

Exclusion

Exclusion Criteria:

  • Perforated gastric ulcer or duodenal ulcer treated within 24 hours of the onset ofsymptoms.

  • Traumatic injury to the bowel (including iatrogenic or intra-operative) treatedwithin 12 hours of injury.

  • Uncomplicated diverticulitis defined as an episode with a short history and withclinical signs of diverticulitis, with an increased body temperature andinflammatory parameters, verified by computed tomography (CT), and without any signof complications such as abscess, free air or fistula.

  • Grade 1 to 3 appendicitis. To be eligible patient must have Grade 4 or 5appendicitis defined by the 2017 American Association for the Surgery Trauma GradingSystem with either generalised peritonitis at surgery, or no or partial sourcecontrol e.g. radiological drainage

  • Non-perforated cholecystitis.

  • Ischemic or necrotic intestine without perforation

  • Uterine perforation following uterine surgery treated <six hours following injury.

  • cIAIs with a low risk of complications who may receive more than 72 hoursantibiotics are not intended to be included, such as those listed above. Traumaticinjury to the bowel (including iatrogenic or intra-operative) treated within 12hours of injury, Uterine perforation following uterine surgery treated within sixhours of injury, Perforated gastric ulcer or duodenal ulcer treated within 24 hoursof the onset of symptoms). Clinician assessment on the eligibility of patientsreceiving more than 72 hours of in-patient surgical care and antibiotics for theircIAI may be required in patients who have clinically improved at this point and donot require active surgical care but remain in hospital and on antibiotics.

  • Current enrolment in another trial dictating antibiotic treatment duration.

  • Previous Clostridium difficile infection

  • Infected necrotic pancreatitis

  • Concomitant infection requiring ≥4 weeks antibiotic therapy including Intra-hepaticabscess/es planned to be treated with fixed-extended-duration antibiotics of 4 to 6weeks antibiotics, osteomyelitis, and endocarditis.

  • Peritoneal dialysis

  • Previously recruited for the EXTEND trial

  • Treatment with Interleukin-6 Inhibitors

  • High likelihood of death within 72 hours of cIAI randomisation in the opinion of thelocal Investigator

  • Limitations in treatment decided before inclusion. Limitations in treatment thatexclude patients from the EXTEND trial are those clinical decisions linked to anexpectation the patient will die during this episode of infection.

  • Patient with persistent cIAI of more than 6 months duration

A maximum of 20% of participants entering the trial can have a source of cIAI as the appendix. If 230 patients with appendix as the source are recruited, this will become an exclusion criteria for subsequent patients.

Note: There are absolute exclusions that preclude trial participation. These include: C. difficile infection, Infected necrotic pancreatitis, Concomitant infection requiring ≥4 weeks antibiotic therapy, Treatment with Interleukin-6 Inhibitors, High likelihood of death within 72 hours of randomisation, Limitations in treatment decided before inclusion, Peritoneal dialysis, Previously recruited for the EXTEND trial, Patient with persistent cIAI of more than 6 months duration and a patient with persistent cIAI of more than 6 months duration. If a patient has two intraabdominal infections, the presence of one of the following ineligible infections does not make a patient ineligible if the other cIAI is eligible: Perforated gastric ulcer or duodenal ulcer treated within 24 hours of the onset of symptoms, Traumatic injury to the bowel (including iatrogenic or intra-operative) treated within 12 hours of injury, Uncomplicated diverticulitis, Ineligible cases of appendicitis (see exclusion criteria above), Uncomplicated cholecystitis, Ischemic or necrotic intestine without perforation, Uterine perforation following uterine surgery treated within six hours of injury or cIAI with a low risk of complications.

Study Design

Total Participants: 1166
Treatment Group(s): 2
Primary Treatment: Antibiotic - fixed-extended-duration
Phase: 3
Study Start date:
October 10, 2022
Estimated Completion Date:
December 31, 2025

Study Description

UK data suggests that current treatment for complicated intra-abdominal infections (cIAIs) results in unacceptably high rates of cIAI relapse and extra-abdominal infection. As a guiding rule, shorter antibiotic durations are important to combat antimicrobial resistance, but this is not true when these shorter courses need repeating and result in more days in hospital. Optimal care for patients should be our primary concern.

The EXTEND trial aims to find out whether a fixed extended duration of 28 days of antibiotics is superior to the current standard duration (typically 7-18 days) based on clinical outcomes and quality of life assessed over 180 days of follow up. Cost effectiveness will also be determined.

A target of 1166 patients will be recruited from ICUs and hospital in-patient wards across approximately 30 NHS trust hospitals. Only patients that are able provide consent (or those with a consultee able to confirm whether the patient would wish to be included in the study) can take part in the trial. They will receive antibiotics as prescribed by their treating clinician, but the duration of treatment will be determined by randomisation. Patients will have equal chance of randomisation to the standard care arm, in which the antibiotic duration will be determined by the treating clinician, or the intervention arm, a fixed duration of 28 days treatment.

Patients (or a personal consultee) will complete a quality of life questionnaire at baseline and 30, 60 and 180 days after randomisation. At follow-up timepoints they will also complete questionnaires on antibiotic use and health care resource use. Hospital notes will be used to collect data on inpatient admissions, relapse and further infections.

The study is Sponsored by the University of Leeds

Connect with a study center

  • Cwm Taf Morgannwg University Health Board,

    Abercynon,
    United Kingdom

    Active - Recruiting

  • NHS Grampian

    Aberdeen,
    United Kingdom

    Active - Recruiting

  • Hywel Dda University Health Board

    Aberystwyth,
    United Kingdom

    Active - Recruiting

  • Buckinghamshire Healthcare NHS Trust

    Aylesbury,
    United Kingdom

    Active - Recruiting

  • UniversityHospitals Birmingham NHS Foundation Trust

    Birmingham,
    United Kingdom

    Active - Recruiting

  • Bolton NHS Foundation Trust

    Bolton,
    United Kingdom

    Active - Recruiting

  • United Lincolnshire Hospitals NHS Trust - Pilgrim Hospital Boston

    Boston,
    United Kingdom

    Active - Recruiting

  • University Hospitals Sussex NHS Foundation Trust

    Brighton,
    United Kingdom

    Active - Recruiting

  • North Bristol NHS Trust

    Bristol,
    United Kingdom

    Site Not Available

  • North Cumbria Integrated Care NHS Foundation Turst

    Carlisle,
    United Kingdom

    Active - Recruiting

  • Chesterfield Royal Hospital NHS Foundation Trust

    Chesterfield,
    United Kingdom

    Active - Recruiting

  • University Hospital Coventry & Warwickshire

    Coventry,
    United Kingdom

    Active - Recruiting

  • County Durham and Darlington NHS Foundation Trust

    Darlington,
    United Kingdom

    Active - Recruiting

  • Northern Lincolnshire and Goole NHS Foundation Trust - Grimsby

    Grimsby,
    United Kingdom

    Active - Recruiting

  • Hull University Teaching Hospitals NHS Trust

    Hull,
    United Kingdom

    Active - Recruiting

  • East Suffolk and North Essex NHS Foundation Trust

    Ipswich,
    United Kingdom

    Active - Recruiting

  • Leeds Teaching Hospitals NHS Trust

    Leeds,
    United Kingdom

    Active - Recruiting

  • University Hospitals of Leicester NHS Trust

    Leicester,
    United Kingdom

    Active - Recruiting

  • Chelsea and Westminster Hospital NHS Foundation Trust

    London,
    United Kingdom

    Active - Recruiting

  • Guys and St Thomas' NHS Foundation Trust

    London,
    United Kingdom

    Active - Recruiting

  • Imperial College Healthcare NHS Trust

    London,
    United Kingdom

    Active - Recruiting

  • King'S College Hospital Nhs Foundation Trust

    London,
    United Kingdom

    Active - Recruiting

  • East Cheshire NHS Trust

    Macclesfield,
    United Kingdom

    Active - Recruiting

  • Manchester University NHS Foundation Trust

    Manchester,
    United Kingdom

    Active - Recruiting

  • Aneurin Bevan University Health Board

    Newport,
    United Kingdom

    Site Not Available

  • Norfolk and Norwich University Hospitals NHS Foundation Trust

    Norwich,
    United Kingdom

    Active - Recruiting

  • Nottingham University Hospital NHS Trust

    Nottingham,
    United Kingdom

    Active - Recruiting

  • University Hospitals Plymouth NHS Trust

    Plymouth,
    United Kingdom

    Active - Recruiting

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Preston,
    United Kingdom

    Active - Recruiting

  • Barking, Havering and Redbridge University Hospitals Nhs Trust

    Romford,
    United Kingdom

    Active - Recruiting

  • East Sussex Hospitals NHS Trust

    Saint Leonards-on-Sea,
    United Kingdom

    Active - Recruiting

  • Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield,
    United Kingdom

    Active - Recruiting

  • North Tees and Hartlepool NHS Foundation Trust

    Stockton-on-Tees,
    United Kingdom

    Active - Recruiting

  • Sherwood Forest Hospitals NHS Foundation Trust

    Sutton In Ashfield,
    United Kingdom

    Active - Recruiting

  • Royal Cornwall Hospitals NHS Trust

    Truro,
    United Kingdom

    Active - Recruiting

  • University Hospitals Sussex NHS Foundation Trust

    Worthing,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.